Drucker Wealth 3.0 LLC Has $893,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Drucker Wealth 3.0 LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,704 shares of the medical instruments supplier’s stock after buying an additional 77 shares during the quarter. Drucker Wealth 3.0 LLC’s holdings in Becton, Dickinson and Company were worth $893,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BDX. Charles Schwab Investment Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares during the last quarter. M&G Plc increased its stake in Becton, Dickinson and Company by 0.9% in the 2nd quarter. M&G Plc now owns 709,259 shares of the medical instruments supplier’s stock valued at $165,967,000 after buying an additional 6,052 shares during the last quarter. Benson Investment Management Company Inc. lifted its position in Becton, Dickinson and Company by 13.2% during the 3rd quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock worth $5,380,000 after buying an additional 2,602 shares in the last quarter. Swedbank AB boosted its stake in shares of Becton, Dickinson and Company by 1.8% during the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock worth $36,367,000 after buying an additional 2,729 shares during the last quarter. Finally, Curi RMB Capital LLC grew its holdings in shares of Becton, Dickinson and Company by 18.1% in the 3rd quarter. Curi RMB Capital LLC now owns 84,873 shares of the medical instruments supplier’s stock valued at $20,463,000 after acquiring an additional 13,030 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BDX has been the topic of a number of recent analyst reports. Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $283.50.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $220.02 on Monday. The stock has a fifty day moving average of $232.60 and a 200-day moving average of $233.59. The stock has a market capitalization of $63.61 billion, a P/E ratio of 37.04, a price-to-earnings-growth ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the business posted $3.42 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.89%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.